Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • 2023 Elections
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • 2023 Elections
No Result
View All Result
Nairametrics
No Result
View All Result
Home Industries Company News

Why 2017 was a tough year for Glaxosmithkline Nigeria

Onome OhwovoriolebyOnome Ohwovoriole
5 years ago
in Company News, Stock Market
Why 2017 was a tough year for Glaxosmithkline  Nigeria

L-R: Non Executive Director, GlaxoSmithKline Consumer Nigeria Plc (GSK), Mr. Samuel Kuye; Managing Director, GSK, Mr. Dayanand Thandalam Spiral; Chairman, GSK, Mr. Edmund Onuzo; and Company Secretary, Uche Uwechia, during the 45th Annual General Meeting & Extra ordinary General Meeting

Share on FacebookShare on TwitterShare on Linkedin

GlaxoSmithKline Consumer Nigeria Plc yesterday released its financial statements for the year ended December 2017. While revenue increased from ₦14.3 billion in 2016 to ₦16.0 billion in 2017, gross profit fell sharply from ₦8.9 billion in 2016 to ₦4.4 billion in 2017.

Profit before tax increased from ₦185 million in 2016 to ₦1.1 billion in 2017. Profit after tax, however, fell sharply from ₦2.3 billion in 2016 to ₦486 million in 2017.

Despite the sharp fall in profit, the company has opted to pay a special dividend of ₦7.10 from its retained earnings and ₦0.40 dividend from the retained portion of the pioneer earning balance.

Cost of Sales up by over 100%

The company’s cost of sales jumped massively from ₦5.4 billion in 2016 to ₦11.6 billion in 2017. While overhead costs dropped sharply from ₦930million in 2016 to ₦154 million in 2017, materials consumed jumped from ₦4.4 billion in 2016 to ₦11.3 billion in 2017.

This led to the company’s operating segments of consumer healthcare and pharmaceuticals making losses of ₦701 million and ₦15.5 million respectively in 2017.

Investment income saved the day

But for the huge spike in investment income, the company would most likely have made a loss in 2017. Investment income rose from ₦171 million in 2016 to ₦1.1 billion in 2017. This was driven largely by interest on short-term deposits. Interest rates spiked in 2017 in tandem with rising inflation and an increase in government borrowing.

GlaxoSmithKline Consumer Nigeria Plc was incorporated in 1971. 46.1 % of its issued shares are held by GlaxoSmithKline United Kingdom and the rest by Nigerian shareholders. The principal activities of the company are manufacturing, marketing and distribution of consumer healthcare and pharmaceutical products.

 

 

 

Related

Tags: 2017 FY resultsGSK PlcQuickTakes

Comments 2

  1. Anonymous says:
    March 25, 2018 at 3:39 pm

    Please can someone kindly explain to me the different between special dividend and ordinary dividend, just wants to know because GSK plc said dey are giving N7.10 as special dividend and 0.40k as ordinary dividend.

    Reply
    • Nairametrics says:
      March 25, 2018 at 10:57 pm

      A Special dividend is one that is issued by a company out of profits it made from Extra-ordinary income. Extra-Ordinary income refers to an income that a business makes upon unusual circumstances. In this case, GSK sold its Drinks Business, so it is the profit it made from that sale that it is sharing to its shareholders.

      Reply

Leave a Reply Cancel reply

Press one
hfm
Mega Millions
fidelity banner
SME
HFM
Patricia





NM newsletters

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • DSS raises alarm over planned violent protest, warns politicians peddling fake news, hate speech
  • Top skills women need to gain financial literacy – Sola Adesakin
  • Why we sued aviation ministry, FAAN over airports concession – National Union of Air Transport Employees

Follow us on social media:

Recent News

Short Take: DSS moves to social media with Instagram, Facebook, Twitter accounts 

DSS raises alarm over planned violent protest, warns politicians peddling fake news, hate speech

March 25, 2023
Meet Sola Adesakin the woman making impact in the financial world across Africa

Top skills women need to gain financial literacy – Sola Adesakin

March 25, 2023
  • Home
  • Exclusives
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Lifestyle
  • Opinions
  • 2023 Elections

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • 2023 Elections

© 2023 Nairametrics

error: Alert: Content selection is disabled!!